Status:
COMPLETED
Role of Famotidine in the Clinical Improvement of COVID-19 Patients.
Lead Sponsor:
Chattogram General Hospital
Collaborating Sponsors:
M Abdur Rahim Medical College and Hospital
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Covid19
Eligibility:
All Genders
16-80 years
Phase:
PHASE3
Brief Summary
This study is aimed to investigate the effect of Famotidine in the clinical recovery of COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medi...
Eligibility Criteria
Inclusion
- SARS-CoV-2 infection confirmed by RT PCR or CT Chest.
- Severe COVID-19 patients require hospitalization under HDU/ICU.
Exclusion
- Patients with severe and/or uncontrolled medical conditions with significantly compromised organ function.
- Patients who were hospitalized from the before due to other reasons.
- Contraindication / possible drug interaction with Famotidine with existing therapy.
- Immunocompromised patients.
- Pregnancy, Pulmonary Tuberculosis, AIDS
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2021
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT04504240
Start Date
August 1 2020
End Date
April 15 2021
Last Update
October 26 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chattogram General Hospital
Chittagong, Bangladesh, 4000
2
M. Abdur Rahim Medical College Hospital
Dinājpur, Bangladesh